肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2019 ASCCP共识指南：宫颈癌筛查和癌前病变管理

2020-04-01 美国阴道镜检查和宫颈病理学会 J Low Genit Tract Dis. 2020 Apr;24(2):102-131.

宫颈癌癌前病变

本文是对2012年宫颈癌筛查和癌前病变管理指南共识的更新，2019年版指南依据最新关于HPV自然史和宫颈癌变的理解提出指导建议。

中文标题：

2019 ASCCP共识指南：宫颈癌筛查和癌前病变管理

英文标题：

2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

发布机构：

美国阴道镜检查和宫颈病理学会

发布日期：

2020-04-01

简要介绍：

本文是对2012年宫颈癌筛查和癌前病变管理指南共识的更新，2019年版指南依据最新关于HPV自然史和宫颈癌变的理解提出指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=2e8321c0018923d9, title=2019 ASCCP共识指南：宫颈癌筛查和癌前病变管理, enTitle=2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors., guiderFrom=J Low Genit Tract Dis. 2020 Apr;24(2):102-131., authorId=0, author=, summary=本文是对2012年宫颈癌筛查和癌前病变管理指南共识的更新，2019年版指南依据最新关于HPV自然史和宫颈癌变的理解提出指导建议。, cover=https://img.medsci.cn/2020418/1587139333380_2020535.jpg, journalId=0, articlesId=null, associationId=749, associationName=美国阴道镜检查和宫颈病理学会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Apr 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本文是对2012年宫颈癌筛查和癌前病变管理指南共识的更新，2019年版指南依据最新关于HPV自然史和宫颈癌变的理解提出指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1402, tagName=宫颈癌), TagDto(tagId=5020, tagName=癌前病变)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21053, categoryName=梅斯医学-宫颈癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5020, guiderKeyword=癌前病变, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=14510, appHits=884, showAppHits=102, pcHits=5766, showPcHits=13627, likes=7, shares=48, comments=32, approvalStatus=1, publishedTime=Sat Apr 18 00:02:29 CST 2020, publishedTimeString=2020-04-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Apr 18 00:02:20 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 12:18:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击：
评论区 (27)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1003456, encodeId=cd361003456af, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee955143876, createdName=146809f3m07暂无昵称, createdTime=Wed Jul 28 22:24:23 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997928, encodeId=27b599e928ec, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72b95545223, createdName=敬敬的, createdTime=Fri Jul 09 11:52:50 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995439, encodeId=5c28995439c3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/4898b9d9447c4a8a99b56ae30ddaa457/64b602c8dd9448b8bd886160665ab816.jpg, createdBy=17d45539335, createdName=木由0, createdTime=Fri Jul 02 17:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977524, encodeId=f5769e7524d5, content=有学习到，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/c582e34dffd844118ae8b268544ea803/7d01ec9d114d4ffcade0890edec85110.jpg, createdBy=95475535653, createdName=宝宝呼啦, createdTime=Mon Jun 28 10:44:32 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977415, encodeId=9dda9e741530, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3875535363, createdName=zzyt981, createdTime=Sun Jun 27 21:20:39 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-07-28 146809f3m07暂无昵称

    非常感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1003456, encodeId=cd361003456af, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee955143876, createdName=146809f3m07暂无昵称, createdTime=Wed Jul 28 22:24:23 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997928, encodeId=27b599e928ec, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72b95545223, createdName=敬敬的, createdTime=Fri Jul 09 11:52:50 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995439, encodeId=5c28995439c3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/4898b9d9447c4a8a99b56ae30ddaa457/64b602c8dd9448b8bd886160665ab816.jpg, createdBy=17d45539335, createdName=木由0, createdTime=Fri Jul 02 17:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977524, encodeId=f5769e7524d5, content=有学习到，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/c582e34dffd844118ae8b268544ea803/7d01ec9d114d4ffcade0890edec85110.jpg, createdBy=95475535653, createdName=宝宝呼啦, createdTime=Mon Jun 28 10:44:32 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977415, encodeId=9dda9e741530, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3875535363, createdName=zzyt981, createdTime=Sun Jun 27 21:20:39 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-07-09 敬敬的

    谢谢分享，非常好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1003456, encodeId=cd361003456af, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee955143876, createdName=146809f3m07暂无昵称, createdTime=Wed Jul 28 22:24:23 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997928, encodeId=27b599e928ec, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72b95545223, createdName=敬敬的, createdTime=Fri Jul 09 11:52:50 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995439, encodeId=5c28995439c3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/4898b9d9447c4a8a99b56ae30ddaa457/64b602c8dd9448b8bd886160665ab816.jpg, createdBy=17d45539335, createdName=木由0, createdTime=Fri Jul 02 17:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977524, encodeId=f5769e7524d5, content=有学习到，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/c582e34dffd844118ae8b268544ea803/7d01ec9d114d4ffcade0890edec85110.jpg, createdBy=95475535653, createdName=宝宝呼啦, createdTime=Mon Jun 28 10:44:32 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977415, encodeId=9dda9e741530, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3875535363, createdName=zzyt981, createdTime=Sun Jun 27 21:20:39 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-07-02 木由0

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1003456, encodeId=cd361003456af, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee955143876, createdName=146809f3m07暂无昵称, createdTime=Wed Jul 28 22:24:23 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997928, encodeId=27b599e928ec, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72b95545223, createdName=敬敬的, createdTime=Fri Jul 09 11:52:50 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995439, encodeId=5c28995439c3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/4898b9d9447c4a8a99b56ae30ddaa457/64b602c8dd9448b8bd886160665ab816.jpg, createdBy=17d45539335, createdName=木由0, createdTime=Fri Jul 02 17:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977524, encodeId=f5769e7524d5, content=有学习到，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/c582e34dffd844118ae8b268544ea803/7d01ec9d114d4ffcade0890edec85110.jpg, createdBy=95475535653, createdName=宝宝呼啦, createdTime=Mon Jun 28 10:44:32 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977415, encodeId=9dda9e741530, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3875535363, createdName=zzyt981, createdTime=Sun Jun 27 21:20:39 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-06-28 宝宝呼啦

    有学习到，谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1003456, encodeId=cd361003456af, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee955143876, createdName=146809f3m07暂无昵称, createdTime=Wed Jul 28 22:24:23 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997928, encodeId=27b599e928ec, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72b95545223, createdName=敬敬的, createdTime=Fri Jul 09 11:52:50 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995439, encodeId=5c28995439c3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/4898b9d9447c4a8a99b56ae30ddaa457/64b602c8dd9448b8bd886160665ab816.jpg, createdBy=17d45539335, createdName=木由0, createdTime=Fri Jul 02 17:12:38 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977524, encodeId=f5769e7524d5, content=有学习到，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/c582e34dffd844118ae8b268544ea803/7d01ec9d114d4ffcade0890edec85110.jpg, createdBy=95475535653, createdName=宝宝呼啦, createdTime=Mon Jun 28 10:44:32 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977415, encodeId=9dda9e741530, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3875535363, createdName=zzyt981, createdTime=Sun Jun 27 21:20:39 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-06-27 zzyt981

    好文章

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

宫颈癌微创手术的中国专家共识

中华医学会妇科肿瘤学分会 · 2019-11-01

2019专家建议：接受贝伐单抗治疗的卵巢癌和宫颈癌患者高血压的管理

国外肿瘤科相关专家小组（统称） · 2019-06-11

宫颈癌诊疗规范（2018年版）

中华人民共和国国家卫生健康委员会 · 2018-12-13

2017 JSGO指南：宫颈癌的治疗

日本妇科肿瘤学会(JSGO,Japan Society of Gynecologic Oncology) · 2018-10-05

拓展阅读

中国早期食管鳞状细胞癌及癌前病变筛查与诊治共识（2015年，北京）

中华医学会消化病学分会(CSGE,Chinese Society Of Gastroenterology) · 2016-01-30

2018德国HPV感染及其相关病变的诊疗指南读解

暂未更新 · 2018-10-30

2019 ESGE/EHMSG/ESP/SPED指南：胃上皮癌前病变的管理

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2019-03-06

肝细胞癌癌前病变的诊断和治疗多学科专家共识（2020版）

中华医学会肝病学分会(Chinese Society of Hepatology, CMA) · 2020-03-15

中国胃黏膜癌前状态和癌前病变的处理策略专家共识（2020年）

中华医学会消化病学分会(CSGE,Chinese Society Of Gastroenterology) · 2020-11-30